Healthtech startup Confido Health has secured $12.5 million in a Series A extension, bringing its total funding to $22.5 million. The company focuses on automating administrative tasks like insurance verification and scheduling for healthcare providers. Investors include Z47, Blume Ventures, and Together Fund, with the capital earmarked for scaling its CareOS platform across new medical specialties.
Confido Health, a New York-based startup, has raised $12.5 million in a Series A extension, led by the venture capital firm Z47. This brings the company's total funding for its Series A round to $22.5 million. Existing investors, including Indian-backed venture firms Blume Ventures and Together Fund, also participated in the funding round. Healthcare private equity veteran Justin Saks has joined the company as a board adviser to support its expansion strategy.
Founded in 2022 by Chetan Reddy and Vichar Shroff, Confido Health is building software that acts as a virtual workforce for medical practices. The company’s flagship product, CareOS, uses artificial intelligence to automate manual administrative tasks that can often slow down healthcare operations. These tasks include insurance verification, patient scheduling, managing medical referrals, and processing payment follow-ups. A key feature of the software is its ability to integrate with over 50 existing electronic health records and practice management systems, allowing clinics to use the AI tool without replacing their current IT infrastructure.
The startup is pursuing a specific business model by partnering with large, multi-location healthcare organizations, particularly those supported by private equity firms. By working with these investors, Confido Health aims to deploy its technology across entire networks of medical practices simultaneously. This strategy is intended to reduce operational costs and administrative burdens, which are common pain points for large, fragmented healthcare networks.
With this fresh capital, the company plans to broaden its AI capabilities by developing specialized workflows for new medical sectors, including ophthalmology, physical therapy, dental care, and primary care. By deploying engineering teams to work closely with the platform, the company hopes to address the technical friction that often occurs when installing new software into legacy systems.
For investors monitoring the healthtech sector, the growth of this company highlights the rising demand for AI-driven efficiency in medical administration. However, success will depend on the company's ability to successfully scale its technology across diverse and complex healthcare environments. Key monitorables for the company’s future performance will include the rate of adoption among large healthcare networks, the successful integration of its software with legacy systems, and the ability to maintain performance quality as it expands into specialized medical fields.